Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeneDx Holdings Corp.WGS · Entity 1634 | CHIEF FINANCIAL OFFICER | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeneDx Holdings Corp.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 48,673 |
Reported balance
After 2026-09-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-16 · Exercise / conversion · Acquired 7,197 · Balance 48,673 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. |
| Class A Common StockSEC Table I · non-derivative | Direct | 48,087 |
Reported balance
After 2026-09-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-16 · Sale · Disposed 586 · Balance 48,087 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.23 to $94.855 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 4 through 7 of this Form 4. |
| Class A Common StockSEC Table I · non-derivative | Direct | 48,035 |
Reported balance
After 2026-09-16 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-16 · Sale · Disposed 52 · Balance 48,035 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.29 to $95.52 per share, inclusive. |
| Class A Common StockSEC Table I · non-derivative | Direct | 47,494 |
Reported balance
After 2026-09-16 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-09-16 · Sale · Disposed 541 · Balance 47,494 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.445 to $97.40 per share, inclusive. |
| Class A Common StockSEC Table I · non-derivative | Direct | 46,024 |
Reported balance
After 2026-09-16 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-09-16 · Sale · Disposed 1,470 · Balance 46,024 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.565 to $98.535 per share, inclusive. |
| Class A Common StockSEC Table I · non-derivative | Direct | 44,945 |
Reported balance
After 2026-09-16 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2026-09-16 · Sale · Disposed 1,079 · Balance 44,945 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.60 to $99.305 per share, inclusive. F8: Following the reported sale undertaken to satisfy tax withholding liabilities, in addition to the 44,945 shares of Class A Common Stock beneficially owned by the Reporting Person, the Reporting Person held RSUs representing contingent rights to receive up to an aggregate 71,667 shares of the Issuer's Class A Common Stock and options to purchase up to an aggregate 25,906 shares of Class A Common Stock, which RSUs and options vest according to their respective terms. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 14,393 |
Reported balance
After 2026-09-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-16 · Exercise / conversion · Disposed 7,197 · Balance 14,393 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F9: 6.25% of the total award vested or vests quarterly, with the first tranche vested on June 16, 2023, subject to the Reporting Person's continued service to the Issuer on each vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.23 to $94.855 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 4 through 7 of this Form 4.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.29 to $95.52 per share, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.445 to $97.40 per share, inclusive.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.565 to $98.535 per share, inclusive.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.60 to $99.305 per share, inclusive.
F8: Following the reported sale undertaken to satisfy tax withholding liabilities, in addition to the 44,945 shares of Class A Common Stock beneficially owned by the Reporting Person, the Reporting Person held RSUs representing contingent rights to receive up to an aggregate 71,667 shares of the Issuer's Class A Common Stock and options to purchase up to an aggregate 25,906 shares of Class A Common Stock, which RSUs and options vest according to their respective terms.
F9: 6.25% of the total award vested or vests quarterly, with the first tranche vested on June 16, 2023, subject to the Reporting Person's continued service to the Issuer on each vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2025 Filed Jul 31, 2025 20:06 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 388 | $105.31 | $40,860.28 |
DisclosureSEC source: 0001415889-25-020715 · form4-07312025_080706.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,757 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · balance_after: Following the reported sales, in addition to the 3,757 shares of Class A common stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned restricted stock units ("RSUs") representing contingent rights to receive up to an aggregate of 135,009 shares of Class A common stock and options to purchase up to an aggregate of 27,152 shares of Class A common stock, which RSUs and options vest according to their respective terms. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 20:06 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 753 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-020715 · form4-07312025_080706.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:04 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,245 | $0.00 Strike: $32.67 | $0.00 |
DisclosureSEC source: 0001415889-25-019667 · form4-07112025_080707.xml · derivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,228 Underlying: Common Stock · 1,245 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on December 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F2 · balance_after: Following the reported sales and option exercise, in addition to the 3,392 shares of Class A common stock and the option to purchase up to 6,228 shares of Class A common stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned restricted stock units ("RSUs") representing contingent rights to receive up to an aggregate of 135,762 shares of Class A common stock and additional options to purchase up to an aggregate of 20,924 shares of Class A common stock, which RSUs and options vest according to their respective terms. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:04 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 5,278 | $93.00 | $490,854.00 |
DisclosureSEC source: 0001415889-25-019667 · form4-07112025_080707.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,392 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. F2 · balance_after: Following the reported sales and option exercise, in addition to the 3,392 shares of Class A common stock and the option to purchase up to 6,228 shares of Class A common stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned restricted stock units ("RSUs") representing contingent rights to receive up to an aggregate of 135,762 shares of Class A common stock and additional options to purchase up to an aggregate of 20,924 shares of Class A common stock, which RSUs and options vest according to their respective terms. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:04 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 1,245 | $32.67 | $40,674.15 |
DisclosureSEC source: 0001415889-25-019667 · form4-07112025_080707.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 18:31 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 346 | $91.88 | $31,790.86 |
DisclosureSEC source: 0001415889-25-019274 · form4-07032025_060735.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,425 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.44 to $92.44 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 18:31 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 998 | $90.86 | $90,680.38 |
DisclosureSEC source: 0001415889-25-019274 · form4-07032025_060735.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,771 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.366 to $91.2988 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:14 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 7,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017665 · form4-06182025_080655.xml · derivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,378 Underlying: Class A Common Stock · 7,197 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:14 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 3,729 | $64.77 | $241,538.52 |
DisclosureSEC source: 0001415889-25-017665 · form4-06182025_080655.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,769 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:14 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 7,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017665 · form4-06182025_080655.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 20:05 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 2,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-016651 · form4-06112025_080657.xml · derivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,773 Underlying: Class A Common Stock · 2,462 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 20:05 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 1,266 | $72.55 | $91,848.30 |
DisclosureSEC source: 0001415889-25-016651 · form4-06112025_080657.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,301 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 20:05 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 2,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-016651 · form4-06112025_080657.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 21:30 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 370 | $71.26 | $26,366.20 |
DisclosureSEC source: 0001415889-25-015430 · form4-06032025_090655.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,105 F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 21:30 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 718 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015430 · form4-06032025_090655.xml · derivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,586 Underlying: Class A Common Stock · 718 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on December 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on December 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 21:30 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 718 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015430 · form4-06032025_090655.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| April 30, 2025 Filed May 1, 2025 23:46 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | GrantClass A Common Stock | 420 | $56.82 | $23,865.45 |
DisclosureSEC source: 0001415889-25-011696 · form4-05012025_110514.xml · nonDerivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,757 F3 · kind: These shares were acquired under the Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 29, 2025 Filed May 1, 2025 23:46 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 753 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011696 · form4-05012025_110514.xml · derivative · entry 4 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,014 Underlying: Class A Common Stock · 753 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 25% of the total RSUs vest on April 29, 2023 and April 29, 2024, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested on April 29, 2026, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 25% of the total RSUs vest on April 29, 2023 and April 29, 2024, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested on April 29, 2026, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| April 29, 2025 Filed May 1, 2025 23:46 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 388 | $113.09 | $43,878.92 |
DisclosureSEC source: 0001415889-25-011696 · form4-05012025_110514.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,337 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| April 29, 2025 Filed May 1, 2025 23:46 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 753 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011696 · form4-05012025_110514.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| April 09, 2025 Filed Apr 10, 2025 20:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,246 | $0.00 Strike: $32.67 | $0.00 |
DisclosureSEC source: 0001415889-25-010536 · form4-04102025_080417.xml · derivative · entry 11 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,473 Underlying: Common Stock · 1,246 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on December 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date Read SEC document |
| April 09, 2025 Filed Apr 10, 2025 20:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 20 | $97.26 | $1,945.20 |
DisclosureSEC source: 0001415889-25-010536 · form4-04102025_080417.xml · nonDerivative · entry 10 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,726 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. Read SEC document |
| April 09, 2025 Filed Apr 10, 2025 20:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 846 | $96.46 | $81,603.13 |
DisclosureSEC source: 0001415889-25-010536 · form4-04102025_080417.xml · nonDerivative · entry 9 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,746 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.07 to $96.96 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2025 Filed Apr 10, 2025 20:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 1,463 | $95.53 | $139,758.49 |
DisclosureSEC source: 0001415889-25-010536 · form4-04102025_080417.xml · nonDerivative · entry 8 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,592 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.04 to $96.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2025 Filed Apr 10, 2025 20:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 3,122 | $94.60 | $295,334.96 |
DisclosureSEC source: 0001415889-25-010536 · form4-04102025_080417.xml · nonDerivative · entry 7 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,055 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.00 to $94.98 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2025 Filed Apr 10, 2025 20:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 6,810 | $93.26 | $635,112.18 |
DisclosureSEC source: 0001415889-25-010536 · form4-04102025_080417.xml · nonDerivative · entry 6 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,177 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.00 to $93.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2025 Filed Apr 10, 2025 20:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 249 | $86.48 | $21,533.52 |
DisclosureSEC source: 0001415889-25-010536 · form4-04102025_080417.xml · nonDerivative · entry 5 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,987 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. Read SEC document |
| April 09, 2025 Filed Apr 10, 2025 20:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 1,171 | $85.73 | $100,391.24 |
DisclosureSEC source: 0001415889-25-010536 · form4-04102025_080417.xml · nonDerivative · entry 4 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,236 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.25 to $86.14 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2025 Filed Apr 10, 2025 20:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 1,198 | $84.61 | $101,358.59 |
DisclosureSEC source: 0001415889-25-010536 · form4-04102025_080417.xml · nonDerivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,407 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.13 to $84.98 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2025 Filed Apr 10, 2025 20:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 637 | $83.67 | $53,297.09 |
DisclosureSEC source: 0001415889-25-010536 · form4-04102025_080417.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,605 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.07 to $84.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2025 Filed Apr 10, 2025 20:12 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 1,246 | $32.67 | $40,706.82 |
DisclosureSEC source: 0001415889-25-010536 · form4-04102025_080417.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2025 Filed May 9, 2025 21:56 UTC Amendment | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,246 | $0.00 Strike: $32.67 | $0.00 |
DisclosureSEC source: 0001415889-25-012579 · form4a-05092025_090544.xml · derivative · entry 11 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,473 Underlying: Common Stock · 1,246 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on December 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| April 09, 2025 Filed May 9, 2025 21:56 UTC Amendment | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 20 | $97.26 | $1,945.20 |
DisclosureSEC source: 0001415889-25-012579 · form4a-05092025_090544.xml · nonDerivative · entry 10 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,972 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. Read SEC document |
| April 09, 2025 Filed May 9, 2025 21:56 UTC Amendment | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 846 | $96.46 | $81,603.13 |
DisclosureSEC source: 0001415889-25-012579 · form4a-05092025_090544.xml · nonDerivative · entry 9 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,992 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.07 to $96.96 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2025 Filed May 9, 2025 21:56 UTC Amendment | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 1,463 | $95.53 | $139,758.49 |
DisclosureSEC source: 0001415889-25-012579 · form4a-05092025_090544.xml · nonDerivative · entry 8 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,838 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.04 to $96.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2025 Filed May 9, 2025 21:56 UTC Amendment | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 2,693 | $94.61 | $254,774.50 |
DisclosureSEC source: 0001415889-25-012579 · form4a-05092025_090544.xml · nonDerivative · entry 7 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,301 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.00 to $94.98 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2025 Filed May 9, 2025 21:56 UTC Amendment | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 5,993 | $93.28 | $559,009.66 |
DisclosureSEC source: 0001415889-25-012579 · form4a-05092025_090544.xml · nonDerivative · entry 6 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,994 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.00 to $93.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2025 Filed May 9, 2025 21:56 UTC Amendment | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 249 | $86.48 | $21,533.52 |
DisclosureSEC source: 0001415889-25-012579 · form4a-05092025_090544.xml · nonDerivative · entry 5 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,987 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. Read SEC document |
| April 09, 2025 Filed May 9, 2025 21:56 UTC Amendment | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 1,171 | $85.73 | $100,391.24 |
DisclosureSEC source: 0001415889-25-012579 · form4a-05092025_090544.xml · nonDerivative · entry 4 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,236 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.25 to $86.14 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2025 Filed May 9, 2025 21:56 UTC Amendment | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 1,198 | $84.61 | $101,358.59 |
DisclosureSEC source: 0001415889-25-012579 · form4a-05092025_090544.xml · nonDerivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,407 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.13 to $84.98 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2025 Filed May 9, 2025 21:56 UTC Amendment | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 637 | $83.67 | $53,297.09 |
DisclosureSEC source: 0001415889-25-012579 · form4a-05092025_090544.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,605 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.07 to $84.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 09, 2025 Filed May 9, 2025 21:56 UTC Amendment | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 1,246 | $32.67 | $40,706.82 |
DisclosureSEC source: 0001415889-25-012579 · form4a-05092025_090544.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:07 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 16,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009194 · form4-03282025_080356.xml · derivative · entry 4 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,750 Underlying: Class A Common Stock · 16,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 25% of the underlying restricted stock units each vests annually, commencing on March 26, 2025, until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 25% of the underlying restricted stock units each vests annually, commencing on March 26, 2025, until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:07 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 328 | $94.40 | $30,964.41 |
DisclosureSEC source: 0001415889-25-009194 · form4-03282025_080356.xml · nonDerivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,996 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:07 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 8,418 | $95.66 | $805,246.52 |
DisclosureSEC source: 0001415889-25-009194 · form4-03282025_080356.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,324 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:07 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 16,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009194 · form4-03282025_080356.xml · nonDerivative · entry 1 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 01:50 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 3,749 | $96.71 | $362,565.04 |
DisclosureSEC source: 0001415889-25-008281 · form4-03182025_010333.xml · nonDerivative · entry 3 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,492 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.67 to $96.71 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 16, 2025 Filed Mar 18, 2025 01:50 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 7,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008281 · form4-03182025_010333.xml · derivative · entry 6 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,575 Underlying: Class A Common Stock · 7,197 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F6 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F6 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| March 16, 2025 Filed Mar 18, 2025 01:50 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 7,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008281 · form4-03182025_010333.xml · nonDerivative · entry 2 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 01:50 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | GrantRestricted Stock Unit · Derivative | 15,261 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008281 · form4-03182025_010333.xml · derivative · entry 5 Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,261 Underlying: Class A Common Stock · 15,261 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: 25% of the underlying restricted stock units each vests annually, commencing on March 15, 2026, until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F5 · derivative.expiration_date: 25% of the underlying restricted stock units each vests annually, commencing on March 15, 2026, until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.